Slipping Quality Standards Puts Patient's Health At Risk

BMI View: The exacerbation of pressures to offset declining profits from several imminent patent expirations, coupled with the impact of the country's healthcare reform, means that drugmakers in the US are increasingly implementing cost-cutting measures that may directly or indirectly contribute to a increasing number of manufacturing quality issues. We note a growing trend for industry consolidation measures seeking to improve operational efficiencies, including increased outsourcing and off-shoring

To read the full article, please choose one of the following options: